Drug intelligence / Profile preview

NOVO-120

Development stage: Preclinical
Lead developer: Novoron Bioscience

Overview

NOVO-120 is an investigational drug candidate developed by Novoron Bioscience, a preclinical biotechnology company focused on therapies for brain and spinal cord injuries. It is being evaluated for traumatic spinal cord injury (SCI), with a specific focus on treating bladder dysfunction and promoting nerve fiber (axon) regrowth. The drug is designed to block signals that typically inhibit nerve regeneration after injury.

Targets

LRP1 (Prolow-density lipoprotein receptor-related protein 1)

Beyond the preview

Go deeper on NOVO-120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOVO-120.

Explore the full profile